Analyst Moves: PFE, VZ, MU

Market News Video
September 03, 2013 AT 4:22 PM
This morning, Leerink Swann increased its price target on shares of Pfizer (PFE) to $28.50 as international sales of Lyrica could boost earnings at the pharmaceutical giant. In the report, Leerink increased its EPS estimates and maintained its market perform rating.